Sustainable growth, Canadian roots
Investor relations centre
Prometic Bioproduction delivers resilient plasma-derived therapeutics with disciplined governance and ESG leadership.
Performance highlights
Key indicators showcasing Prometic’s operational strength and market momentum.
$420M
FY2023 revenue, +14% year-over-year
31%
Adjusted EBITDA margin driven by process efficiency
$68M
R&D investment into new plasma programs
19
Active global market authorisations supported
Financial reports
Quarterly and annual disclosures prepared in accordance with IFRS.
Governance & leadership
Transparent oversight led by experienced board members and executives.
Board committees covering audit, science & innovation, and ESG performance.
Code of ethics reaffirmed annually with bilingual training.
Independent whistleblower hotline managed by third-party specialists.
Governance documents
Investor contact
Reach our investor relations team for briefings, meetings, or shareholder inquiries.
Isabelle Fournier, VP Investor Relations
investors@prometicbio.ca • +1 (514) 555-2084
Book a meeting